This information was originally presented on September 20, 2014, at the NCCN 9th Annual Congress: Hematologic Malignancies™ held in New York, New York.

This information was originally presented on September 21, 2013, at the NCCN 8^th Annual Congress: Hematologic Malignancies™ held in New York, New York.

This information was originally presented on September 21, 2013, at the NCCN 8^th Annual Congress: Hematologic Malignancies™ held in New York, New York.

Although frontline treatment of advanced Hodgkin lymphoma (HL) produces high cure rates, disease either will not respond to or will relapse after initial therapy in approximately a quarter of patients.

This information was originally presented on September 14, 2012, at the NCCN 7^th Annual Congress: Hematologic Malignancies™ held in New York, New York.

This information was originally presented on September 14, 2012, at the NCCN 7^th Annual Congress: Hematologic Malignancies™ held in New York, New York.

Vaccination is an important strategy for preventing infections in patients with hematologic malignancies. Hematopoietic cell transplant (HCT) recipients have diminished immunity against vaccine-preventable diseases after transplantation.